Skip to main content

Advertisement

SpringerLink
Log in

Biochemical, pathological and oncological relevance of Gb3Cer receptor

  • Original paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Glycosphingolipids are amphipathic molecules composed of hydrophilic oligosaccharide chain and a hydrophobic ceramide part, located primarily in the membrane microdomains of animal cells. Their oligosaccharide chains make them excellent candidates for the cell surface recognition molecules. Natural glycosphingolipid, globotriaosylceramide (Gal α1-4, Gal β1-4, Glc β1-1, ceramide), is also called CD77 and its expression was previously associated with proliferating centroblasts undergoing somatic hypermutation, but it has been demonstrate that globotriaosylceramide is not a reliable marker to discriminate human centroblasts from centrocytes. Globotriaosylceramide constitutes rare P k blood group antigen on erythrocytes, and it is also known as Burkitt’s lymphoma antigen. On endothelial cells, globotriaosylceramide plays as the receptor for bacterial toxins of the Shiga family, also called verotoxins. Precise biological function and significance of globotriaosylceramide expression on endothelial cells remains to be the subject of many studies and it is believed globotriaosylceramide represents an example of a glycolipid antigen able to transduce a signal leading to apoptosis. In past decade, cancer researches put a great afford in determining new therapeutic agents such as bacterial toxins against tumor malignancies. Reports have demonstrated that verotoxin-1 induces apoptosis in solid tumor cell lines expressing globotriaosylceramide such as astrocytoma, renal cell carcinoma, colon cancer and breast cancer due to verotoxin-1 high specificity and apoptosis-inducing properties, and therefore, it is suggested to be an anticancer agent. Verotoxins have been investigated weather they could reduce treatment side-effects and toxicity to normal tissues and become a new oncological tool in cancer labeling.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hakomori SI. Cell adhesion/recognition and signal transduction through glycosphingolipid microdomain. Glycoconj J. 2000;17:143–51.

    PubMed  CAS  Google Scholar 

  2. Sonnino S, Prinetti A, Mauri L, Chigorno V, Tettamanti G. Dynamic and structural properties of sphingolipids as driving forces for the formation of membrane domains. Chem Rev. 2006;106:2111–25.

    PubMed  CAS  Google Scholar 

  3. Fantini J, Maresca M, Hammache D, Yahi N, Delézay O. Glycosphingolipid (GSL) microdomains as attachment platforms for host pathogens and their toxins on intestinal epithelial cells: activation of signal transduction pathways and perturbations of intestinal absorption and secretion. Glycoconj J. 2001;17:173–9.

    Google Scholar 

  4. Stults CL, Sweeley CC, Macher BA. Glycosphingolipids: structure, biological source, and properties. Method Enzymol. 1989;179:167–214.

    CAS  Google Scholar 

  5. Schnaar RL. Glycosphingolipids in cell surface recognition. Glycobiology. 1991;1:477–85.

    PubMed  CAS  Google Scholar 

  6. Lingwood CA. Role of verotoxin receptors in pathogenesis. Trends Microbiol. 1996;4:147–53.

    PubMed  CAS  Google Scholar 

  7. Konowalchuk J, Dickie N, Stavric S, Speirs JI. Properties of an Escherichia coli cytotoxin. Infect Immun. 1978;20:575–7.

    PubMed  CAS  Google Scholar 

  8. Sandvig K. Shiga toxins. Toxicon. 2001;39:1629–35.

    PubMed  CAS  Google Scholar 

  9. Boyd B, et al. Lipid modulation of glycolipid receptor function. Eur J Biochem. 1994;223:873–8.

    PubMed  CAS  Google Scholar 

  10. Kiarash A, et al. Glycosphingolipid receptor function is modified by fatty acid content. J Biol Chem. 1994;269:11138–46.

    PubMed  CAS  Google Scholar 

  11. Lingwood CA. Aglycone modulation of glycolipid receptor function. Glycoconj J. 1996;13:495–503.

    PubMed  CAS  Google Scholar 

  12. Arab S, Lingwood CA. Intracellular targeting of the endoplasmic reticulum/nuclear envelope by retrograde transport may determine cell hypersensitivity to verotoxin via globotriaosyl ceramide fatty isoform traffic. J Cell Physiol. 1998;177:646–60.

    PubMed  CAS  Google Scholar 

  13. Ling H, et al. Structure of the shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. Biochemistry. 1998;37:1777–88.

    PubMed  CAS  Google Scholar 

  14. Sandvig K, van Deurs B. Entry of ricin and Shiga toxin into cells: molecular mechanisms and medical perspectives. EMBO J. 2000;19:5943–50.

    PubMed  CAS  Google Scholar 

  15. Garred O, van Deurs B, Sandvig K. Furin-induced cleavage and activation of Shiga toxin. J Biol Chem. 1995;270:10817–21.

    PubMed  CAS  Google Scholar 

  16. Endo Y, et al. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and Shiga toxin on eukaryotic ribosomes. Eur J Biochem. 1988;171:45–50.

    PubMed  CAS  Google Scholar 

  17. Mangeney M, et al. Apoptosis induced in Burkitt’s lymphoma cells via Gb3/CD77, a glycolipid antigen. Cancer Res. 1993;53:5314–9.

    PubMed  CAS  Google Scholar 

  18. Fan J, Sammalkorpi M, Haataja M. Formation and regulation of lipid microdomains in cell membranes: theory, modeling, and speculation. FEBS Lett. 2010;584:1678–84.

    PubMed  CAS  Google Scholar 

  19. Gaus K, Chklovskaia E, Fazekas de Groth B, Jessup W, Harder T. Condensation of the plasma membrane at the site of T lymphocyte activation. J Cell Biol. 2005;171:121–31.

    PubMed  CAS  Google Scholar 

  20. Tavano R, et al. CD28 interaction with filamin-A controls lipid raft accumulation at the T-cell immunological synapse. Nat Cell Biol. 2006;8:1270–6.

    PubMed  CAS  Google Scholar 

  21. Chinnapen DJ, Chinnapen H, Saslowsky D, Lencer WI. Rafting with cholera toxin: endocytosis and trafficking from plasma membrane to ER. FEMS Microbiol Lett. 2007;266:129–37.

    PubMed  CAS  Google Scholar 

  22. Kalisiak A, Minniti JG, Oosterwijk E, Old LJ, Scheinberg DA. Neutral glycosphingolipid expression in B-cell neoplasms. Int J Cancer. 1991;49:837–45.

    PubMed  CAS  Google Scholar 

  23. Sandvig K, et al. Pathways followed by ricin and Shiga toxin into cells. Histochem Cell Biol. 2002;117:131–41.

    PubMed  CAS  Google Scholar 

  24. Bonifacino JS, Rojas R. Retrograde transport from endosomes to the trans-Golgi network. Nat Rev Mol Cell Biol. 2006;7:568–79.

    PubMed  CAS  Google Scholar 

  25. Römer W, et al. Shiga toxin induces tubular membrane invaginations for its uptake into cells. Nature. 2007;450:670–5.

    PubMed  Google Scholar 

  26. Mori T, et al. Globotriaosyl ceramide (CD77/Gb3) in the glycolipidenriched membrane domain participates in B-cell receptor-mediated apoptosis by regulating Lyn kinase activity in human B cells. Exp Hematol. 2000;28:1260–8.

    PubMed  CAS  Google Scholar 

  27. Katagiri YU, et al. Activation of Src family kinase yes induced by Shiga toxin binding to globotriaosyl ceramide (Gb3/CD77) in low density, detergent-insoluble microdomains. J Biol Chem. 1999;274:35278–82.

    PubMed  CAS  Google Scholar 

  28. Falguières T, et al. Targeting of Shiga toxin B-subunit to retrograde transport route in association with detergent resistant membranes. Mol Biol Cell. 2001;12:2453–68.

    PubMed  Google Scholar 

  29. Kovbasnjuk O, et al. Role of lipid rafts in Shiga toxin 1 interaction with the apical surface of Caco-2 cells. J Cell Sci. 2001;114:4025–31.

    PubMed  CAS  Google Scholar 

  30. Lencer WI, Saslowsky D. Raft trafficking of AB5 subunit bacterial toxins. Biochim Biophys Acta. 2005;1746:314–21.

    PubMed  CAS  Google Scholar 

  31. Tam P, Lingwood C. Membrane-cytosolic translocation of verotoxin A1-subunit in target cells. Microbiology. 2007;153:2700–10.

    PubMed  CAS  Google Scholar 

  32. Römer W, et al. Actin dynamics drive membrane reorganization and scission in clathrin-independent endocytosis. Cell. 2010;140:540–53.

    PubMed  Google Scholar 

  33. Binnington B, Lingwood D, Nutikka A, Lingwood CA. Effect of globotriaosyl ceramide fatty acid a-hydroxylation on the binding by verotoxin 1 and verotoxin 2. Neurochem Res. 2002;27:807–13.

    PubMed  CAS  Google Scholar 

  34. Newburg D, et al. Susceptibility to hemolytic-uremic syndrome relates to erythrocyte glycosphingolipid patterns. J Infect Dis. 1993;168:476–9.

    PubMed  CAS  Google Scholar 

  35. Lingwood CA. Verotoxin/globotriaosyl ceramide recognition: angiopathy, angiogenesis and antineoplasia. Biosci Rep. 1999;19:345–54.

    PubMed  CAS  Google Scholar 

  36. Kiguchi K, et al. Characteristic expression of globotriaosyl ceramide in human ovarian carcinomaderived cells with anticancer drug resistance. Cancer Sci. 2006;97:1321–6.

    PubMed  CAS  Google Scholar 

  37. Sandvig K, et al. Retrograde transport from the golgi complex to the ER of both Shiga toxin and the nontoxic Shiga B-fragment is regulated by butyric acid and cAMP. J Cell Biol. 1994;126:53–64.

    PubMed  CAS  Google Scholar 

  38. Tam P, et al. Differential intracellular trafficking and binding of verotoxin 1 and verotoxin 2 to globotriaosylceramide-containing lipid assemblies. J Cell Physiol. 2008;216:750–63.

    PubMed  CAS  Google Scholar 

  39. Burger K, Gimpl G, Fahrenholz F. Regulation of receptor function by cholesterol. Cell Mol Life Sci. 2000;57:1577–92.

    PubMed  CAS  Google Scholar 

  40. Chark D, Nutikka A, Trusevych N, Kuzmina J, Lingwood C. Differential carbohydrate epitope recognition of globotriaosyl ceramide by verotoxins and a monoclonal antibody. Eur J Bioch. 2004;271:405–17.

    CAS  Google Scholar 

  41. Smith DC, et al. The association of Shiga-like toxin with detergent-resistant membranes is modulated by glucosylceramide and is an essential requirement in the endoplasmic reticulum for a cytotoxic effect. Mol Biol Cell. 2006;17:1375–87.

    PubMed  CAS  Google Scholar 

  42. Hoey DEE, Currie C, Lingwood CA, Gally DL, Smith DGE. Binding of verotoxin 1 to primary intestinal epithelial cells expressing Gb3 results in trafficking of toxin to lysosomal compartments. Cell Microbiol. 2003;5:85–97.

    PubMed  CAS  Google Scholar 

  43. Khine AA, Firtel M, Lingwood CA. CD77-dependent retrograde transport of CD19 to the nuclear membrane: functional relationship between CD77 and CD19 during germinal center B-cell apoptosis. J Cell Physiol. 1998;176:281–92.

    PubMed  CAS  Google Scholar 

  44. Maloney MD, Lingwood CA. CD19 Has a potential CD77 (Globotriaosyl ceramide)-binding site with sequence similarity to verotoxin B-subunits: implications of molecular mimicry for B cell adhesion and enterohemorrhagic Escherichia coli pathogenesis. J Exp Med. 1994;180:191–201.

    PubMed  CAS  Google Scholar 

  45. Obrig TG, et al. Direct cytotoxic action of Shiga toxin on human vascular endothelial cells. Infect Immun. 1988;56:2373–8.

    PubMed  CAS  Google Scholar 

  46. Ohmi K, Kiyokawa N, Takeda T, Fujimoto J. Human microvascular endothelial cells are strongly sensitive to Shiga toxin. Biochem Biophys Res Commun. 1998;251:137–41.

    PubMed  CAS  Google Scholar 

  47. Holgersson J, Jovall PA, Breimer ME. Glycosphingolipids of human large intestine: detailed structural characterization with special reference to blood group compounds and bacterial receptor structures. J Biochem. 1991;110:120–31.

    PubMed  CAS  Google Scholar 

  48. Schuller S, Frankel G, Phillips AD. Interaction of Shiga toxin from Escherichia coli with human intestinal epithelial cell lines and explants: Stx2 induces epithelial damage in organ culture. Cell Microbiol. 2004;6:289–301.

    PubMed  Google Scholar 

  49. Ramegowda B, Samuel JE, Tesh VL. Interaction of Shiga toxins with human brain microvascular endothelial cells: cytokines as sensitizing agents. J Infect Dis. 1999;180:1205–13.

    PubMed  CAS  Google Scholar 

  50. Eisenhauer PE, et al. Tumor necrosis factor alpha increases human cerebral endothelial cell Gb3 and sensitivity to Shiga toxin. Infect Immun. 2001;69:1889–94.

    PubMed  CAS  Google Scholar 

  51. Stricklett PK, Hughes AK, Ergonul Z, Kohan DE. Molecular basis for up-regulation by inflammatory cytokines of Shiga toxin 1 cytotoxicity and globotriaosylceramide expression. J Infect Dis. 2002;186:976–82.

    PubMed  CAS  Google Scholar 

  52. Ergonul Z, Hughes AK, Kohan DE. Induction of apoptosis of human brain microvascular endothelial cells by Shiga toxin. J Infect Dis. 2003;187:154–8.

    PubMed  CAS  Google Scholar 

  53. Uchida H, et al. Shiga toxins induce apoptosis in pulmonary epithelium–derived cells. J Infect Dis. 1999;180:1902–11.

    PubMed  CAS  Google Scholar 

  54. Takahashi K, Funata N, Ikuta F, Sato S. Neuronal apoptosis and inflammatory responses in the central nervous system of a rabbit treated with Shiga toxin-2. J Neuroinflamm. 2008;5:11–23.

    Google Scholar 

  55. De Rosa MF, et al. Inhibition of multidrug resistance by adamantylgb3, a globotriasylceramide analog. J Biol Chem. 2008;283:4501–11.

    PubMed  Google Scholar 

  56. Bielaszewska M, Karch H. Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium. Thromb Haemost. 2005;94:312–8.

    PubMed  CAS  Google Scholar 

  57. Nakao H, Takeda T. Escherichia coli Shiga toxin. J Nat Toxins. 2000;9:299–313.

    PubMed  CAS  Google Scholar 

  58. Karch H. The role of virulence factors in enterohemorrhagic Escherichia coli (EHEC)-associated hemolytic: uremic syndrome. Semin Thromb Hemost. 2001;27:207–13.

    PubMed  CAS  Google Scholar 

  59. Forsyth KD, et al. Neutrophil-mediated endothelial injury in haemolytic uraemic syndrome. Lancet. 1989;2:411–4.

    PubMed  CAS  Google Scholar 

  60. Morigi M, et al. Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood. 2001;98:1828–35.

    PubMed  CAS  Google Scholar 

  61. Ching JC, Jones NL, Ceponis PJ, Karmali MA, Sherman PM. Escherichia coli shiga-like toxins induce apoptosis and cleavage of poly (ADP-ribose) polymerase via in vitro activation of caspases. Infect Immun. 2002;70:4669–77.

    PubMed  CAS  Google Scholar 

  62. Kiyokawa N, et al. Activation of the caspase cascade during Stx1-induced apoptosis in Burkitt’s lymphoma cells. J Cell Biochem. 2001;81:128–42.

    PubMed  CAS  Google Scholar 

  63. Tétaud C, et al. Two distinct Gb3/CD77 signaling pathways leading to apoptosis are triggered by anti-Gb3/CD77 mAb and verotoxin-1. J Biol Chem. 2003;278:45200–8.

    PubMed  Google Scholar 

  64. Garibal J, Hollville É, Renouf B, Tétaud C, Wiels J. Caspase-8-mediated cleavage of Bid and protein phosphatase 2A-mediated activation of Bax is necessary for Verotoxin-1-induced apoptosis in Burkitt’s lymphoma cells. Cell Signal. 2001;22:467–75.

    Google Scholar 

  65. Lee SY, Cherla RP, Caliskan I, Tesh VL. Shiga toxin 1 induces apoptosis in the human myelogenous leukemia cell line THP-1 by a caspase-8-dependent, tumor necrosis factor-independent mechanism. Infect Immun. 2008;73:5115–26.

    Google Scholar 

  66. Erwert RD, et al. Shiga toxin induces decreased expression of the anti-apoptotic protein Mcl-1 concomitant with the onset of endothelial apoptosis. Microb Pathog. 2003;35:87–93.

    PubMed  CAS  Google Scholar 

  67. Fujii J, et al. Rapid apoptosis induced by Shiga toxin in HeLa cells. Infect Immun. 2003;71:2724–35.

    PubMed  CAS  Google Scholar 

  68. Gariepy J. The use of Shiga-like toxin 1 in cancer therapy. Crit Rev Oncol Hematol. 2001;39:99–106.

    PubMed  CAS  Google Scholar 

  69. LaCasse EC, et al. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation. Blood. 1999;94:2901–10.

    PubMed  CAS  Google Scholar 

  70. Salhia B, Rutka JT, Lingwood C, Nutikka A, Van Furth WR. The treatment of malignant meningioma with verotoxin. Neoplasia. 2002;4:304–11.

    PubMed  CAS  Google Scholar 

  71. Murray LJ, Habeshaw JA, Wiels J, Greaves MF. Expression of Burkitt lymphoma-associated antigen (defined by the monoclonal antibody 38.13) on both normal and malignant germinal-centre B cells. Int J Cancer. 1985;36:561–5.

    PubMed  CAS  Google Scholar 

  72. Ohyama C, et al. Changes in glycolipid expression in human testicular tumor. Int J Cancer. 1990;45:1040–4.

    PubMed  CAS  Google Scholar 

  73. Johansson D, et al. Verotoxin-1 induction of apoptosis in Gb3- expressing human glioma cell lines. Cancer Biol Ther. 2006;5:1211–7.

    PubMed  CAS  Google Scholar 

  74. Arab S, et al. Expression of the verotoxin receptor glycolipid, globotriaosylceramide, in ovarian hyperplasias. Oncol Res. 1997;9:553–63.

    PubMed  CAS  Google Scholar 

  75. Fredman P, Hedberg K, Brezicka T. Gangliosides as therapeutic targets for cancer. BioDrugs. 2003;17:155–67.

    PubMed  CAS  Google Scholar 

  76. Kovbasnjuk O, et al. The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer. Proc Natl Acad Sci USA. 2005;102:19087–92.

    PubMed  CAS  Google Scholar 

  77. Johannes L, Decaudin D. Protein toxins: intracellular trafficking for targeted therapy. Gene Ther. 2005;12:1360–8.

    PubMed  CAS  Google Scholar 

  78. Janssen KP, et al. In vivo tumor targeting using a novel intestinal pathogen-based delivery approach. Cancer Res. 2006;66:7230–6.

    PubMed  CAS  Google Scholar 

  79. Ludwig K, et al. Antibody response to Shiga toxins Stx2 and Stx1 in children with enteropathic hemolytic-uremic syndrome. J Clin Microbiol. 2001;39:2272–9.

    PubMed  CAS  Google Scholar 

  80. Levine MM, et al. Antibodies to shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shigella dysenteriae 1 dysentery. J Clin Microbiol. 1992;30:1636–41.

    PubMed  CAS  Google Scholar 

  81. O’Brien AD, et al. Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr Top Microbiol Immunol. 1992;180:65–94.

    PubMed  Google Scholar 

  82. Vingert B, et al. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Eur J Immunol. 2006;36:1124–35.

    PubMed  CAS  Google Scholar 

  83. Haicheur N, et al. Vt B-subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I restricted presentation of peptides derived from exogenous antigens. J Immunol. 2000;165:3301–8.

    PubMed  CAS  Google Scholar 

  84. Wang H, Griffiths MN, Burton DR, Ghazal P. Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization. Proc Natl Acad Sci USA. 2000;97:847–85.

    PubMed  CAS  Google Scholar 

  85. Haicheur N, et al. The B subunit of Shiga toxin coupled to fullsize antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization. Int Immunol. 2003;15:1–11.

    Google Scholar 

  86. Falguières T. Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool. Mol Cancer Ther. 2008;7:2498–508.

    PubMed  Google Scholar 

  87. Viel T, et al. In vivo tumor targeting by the B-subunit of shiga toxin. Mol Imaging. 2008;7:239–47.

    PubMed  Google Scholar 

  88. Rutjes NW, Binnington BA, Smith CR, Maloney MD, Lingwood CA. Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model. Kidney Int. 2002;62:832–45.

    PubMed  CAS  Google Scholar 

  89. Imberty A, Wimmerová M, Mitchell EP, Gilboa-Garber N. Structures of the lectins from Pseudomonas aeruginosa: insight into the molecular basis for host glycan recognition. Microbes Infect. 2004;6:221–8.

    PubMed  CAS  Google Scholar 

  90. Blanchard B, et al. Structural basis of the preferential binding for globo-series glycosphingolipids displayed by Pseudomonas aeruginosa lectin I. Mol Biol. 2008;383:837–53.

    CAS  Google Scholar 

  91. Distler U, et al. Shiga toxin receptor Gb3Cer/CD77: tumor-association and promising therapeutic target in pancreas and colon cancer. PLoS ONE. 2009;4(8):e6813.

    Google Scholar 

  92. Schuller S, Heuschkel R, Torrente F, Kaper JB, Phillips AD. Shiga toxin binding in normal and inflamed human intestinal mucosa. Microbes Infect. 2007;9:35–9.

    PubMed  Google Scholar 

  93. Ishitoya S, et al. Verotoxin induces rapid elimination of human renal tumor xenografts in SCID mice. J Urol. 2004;171:1309–13.

    PubMed  CAS  Google Scholar 

  94. Arab S, Rutka J, Lingwood C. Verotoxin induces apoptosis and the complete, rapid, long-term elimination of human astrocytoma xenografts in nude mice. Oncol Res. 1999;11:33–9.

    PubMed  CAS  Google Scholar 

  95. Heath-Engel HM, Lingwood CA. Verotoxin sensitivity of ECV304 cells in vitro and in vivo in a xenograft tumour model: VT1 as a tumour neovascular marker. Angiogenesis. 2003;6:129–41.

    PubMed  CAS  Google Scholar 

  96. Johansson D, et al. Expression of verotoxin-1 receptor Gb3 in breast cancer tissue and verotoxin-1 signal transduction to apoptosis. BMC Cancer. 2009;9:67–76.

    PubMed  Google Scholar 

  97. Bornkamm GW, Polack A, Eick D, Berger R, Lenoir GM. Chromosome translocations and Epstein-Barr virus in Burkitt’s lymphoma. Onkologie. 1987;10:196–204.

    PubMed  CAS  Google Scholar 

  98. Jaffe ES, et al. Burkitt’s lymphoma: a single disease with multiple variants. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Blood. 1999;3:1124.

    Google Scholar 

  99. Gordon J, et al. CD40 ligand, Bcl-2, and Bcl-xL spare group I Burkitt lymphoma cells from CD77-directed killing via Verotoxin-1B chain but fail to protect against the holotoxin. Cell Death Differ. 2000;7:785–94.

    PubMed  CAS  Google Scholar 

  100. Cohen A, Hannigan GE, Williams BRG, Lingwood CA. Roles of globotriosyl- and galabiosylceramide in verotoxin binding and high affinity interferon receptor. J Biol Chem. 1987;262:17088–91.

    PubMed  CAS  Google Scholar 

  101. Wiels J, Fellous M, Tursz T. Monoclonal antibody against a Burkitt lymphoma associated antigen. Proc Natl Acad Sci USA. 1981;78:6485–9.

    PubMed  CAS  Google Scholar 

  102. Sakthivel R, Christensson B, Ehlin-Henriksson B, Klein G. Immunophenotypic characterization of follicle-center-cell-derived non-Hodgkin’s lymphomas. Int J Cancer. 1989;43:624–30.

    PubMed  CAS  Google Scholar 

  103. Taga S, et al. Intracellular signalling events in CD77-mediated apoptosis of Burkitt’s lymphoma cells. Blood. 1997;90:2757–67.

    PubMed  CAS  Google Scholar 

  104. Grafton G, Goodall M, Gregory CD, Gordon J. Mechanisms of antigen receptor-dependent apoptosis in human B lymphoma cell lines probed with a panel of 27 monoclonal antibodies. Cell Immunol. 1997;182:45–56.

    PubMed  CAS  Google Scholar 

  105. Michael JM, Lavin MF, Watters DJ. Resistance to radiation-induced apoptosis in Burkitt’s lymphoma cells is associated with defective ceramide signaling. Cancer Res. 1997;57:3600–5.

    PubMed  CAS  Google Scholar 

  106. Furukawa K, et al. Expression of the Gb3/CD77 synthase gene in megakaryoblastic leukemia cells. J Biol Chem. 2002;277:11247–54.

    PubMed  CAS  Google Scholar 

  107. Zhang X-g, et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood. 1994;83:3654–63.

    PubMed  CAS  Google Scholar 

  108. Szczepek AJ, et al. A high frequency of circulating B cells share clonotypic IgH VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single cell and in situ RT-PCR. Blood. 1998;92:2844–55.

    PubMed  CAS  Google Scholar 

  109. Bechtel D, Kurth J, Unkel C, Ku¨ppers R. Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas. Blood. 2005;106:4345–50.

    PubMed  CAS  Google Scholar 

  110. Arbus GS, et al. Verotoxin targets lymphoma infiltrates of patients with post-transplant lymphoproliferative disease. Leukemia Res. 2000;24:857–64.

    CAS  Google Scholar 

  111. Craxton A, Chuang PI, Shu G, Harlan JM, Clark EA. The CD40-inducible Bcl-2 family member A1 protects B Cells from antigen receptor-mediated apoptosis. Cell Immunol. 2000;200:56–62.

    PubMed  CAS  Google Scholar 

  112. Li T, Ramirez K, Palacios R. Distinct patterns of Fas cell surface expression during development of T- or B-lymphocyte lineages in normal, scid, and mutant mice lacking or overexpressing p53, bcl-2, or rag-2 genes. Cell Growth Differ. 1996;7:107–14.

    PubMed  CAS  Google Scholar 

  113. Ghia P, et al. Unbalanced expression of Bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. Blood. 1998;91:224–51.

    Google Scholar 

  114. Holder MJ, et al. Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bcl-2 induction. Eur J Immunol. 1993;23:2368–71.

    PubMed  CAS  Google Scholar 

  115. Traulle C, Coiffier B. Evolving role of rituximab in the treatment of patients with non-Hodgkin’s lymphoma. Future Oncol. 2005;1:297–306.

    PubMed  CAS  Google Scholar 

  116. Béniguel L, et al. identification of germinal center B cells in blood from HIV-infected drug-naive individuals in central Africa. Clin Dev Immunol. 2004;11:23–7.

    PubMed  Google Scholar 

  117. Ramkumar S, Sakac D, Binnington B, Branch DR, Lingwood CA. Induction of HIV-1 resistance: cell susceptibility to infection is an inverse function of globotriaosyl ceramide levels. Glycobiology. 2009;19:76–82.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This work resulted from scientific project “Pathobiochemistry of glycosphingolipid antigens” carried out by support of Ministry of Science, Education and Sports, Republic of Croatia.

Author information

Authors and Affiliations

  1. University of Split School of Medicine, Šoltanska 2, 21000, Split, Croatia

    D. Đevenica

  2. Department of Medical Chemistry and Biochemistry, University of Split School of Medicine, Šoltanska 2, 21000, Split, Croatia

    V. Čikeš Čulić & A. Markotić

  3. University Hospital Split, Spinčićeva 1, 21000, Split, Croatia

    A. Vuica

Authors
  1. D. Đevenica
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Čikeš Čulić
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Vuica
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Markotić
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Đevenica.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Đevenica, D., Čikeš Čulić, V., Vuica, A. et al. Biochemical, pathological and oncological relevance of Gb3Cer receptor. Med Oncol 28 (Suppl 1), 675–684 (2011). https://doi.org/10.1007/s12032-010-9732-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9732-8

Keywords

Search

Navigation